Short Interest in Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) Declines By 24.9%

Key Points

• The short interest in Daiichi Sankyo Co., Ltd. declined by 24.9% in August, falling to 76,400 shares from 101,700 shares at the end of July.
• Daiichi Sankyo's current stock price is $24.27, with a market cap of $45.98 billion and a price-to-earnings ratio of 23.56.
• Nomura Securities has upgraded Daiichi Sankyo to a "strong-buy" rating, contributing to a consensus rating of "Strong Buy" for the stock.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) was the recipient of a large drop in short interest in August. As of August 15th, there was short interest totaling 76,400 shares, adropof24.9% from the July 31st total of 101,700 shares. Based on an average daily volume of 394,600 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily volume of 394,600 shares, the days-to-cover ratio is presently 0.2 days.

Daiichi Sankyo Stock Down 1.1%

Shares of OTCMKTS:DSNKY opened at $24.27 on Monday. The company has a current ratio of 2.53, a quick ratio of 1.85 and a debt-to-equity ratio of 0.06. The firm has a market cap of $45.98 billion and a price-to-earnings ratio of 23.56. The stock's 50-day moving average price is $24.05 and its two-hundred day moving average price is $24.15. Daiichi Sankyo has a 12-month low of $20.92 and a 12-month high of $40.60.

Analysts Set New Price Targets

Separately, Nomura Securities raised shares of Daiichi Sankyo to a "strong-buy" rating in a research note on Friday, June 6th. One equities research analyst has rated the stock with a Strong Buy rating, According to MarketBeat, the stock presently has a consensus rating of "Strong Buy".

Daiichi Sankyo Company Profile

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.